SPDR-1 HSP90 inhibition overcomes resistant to molecular targeted therapy in BRAF(V600E) mutant glioblastoma

The BRAF(V600E) mutation results in the constitutive activation of downstream mitogen activated protein kinase (MAPK) pathway that promotes tumor growth. Recently, molecular targeted therapy using BRAF/MEK inhibitor has been reported for BRAF(V600E) mutant high-grade glioma, but the therapeutic effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasame, Jo, Ikegaya, Naoki, Miyake, Yohei, Hayashi, Takahiro, Oshima, Akito, Homma, Hirokuni, Isoda, Masataka, Takabayashi, Katsuhiro, Yamamoto, Tetsuya, Tateishi, Kensuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648250/
http://dx.doi.org/10.1093/noajnl/vdab159.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648250/
http://dx.doi.org/10.1093/noajnl/vdab159.010

Ejemplares similares